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The trafficking of fatty acids across the membrane and into
downstream metabolic pathways requires their activation to
CoA thioesters. Members of the fatty acid transport protein/
very long chain acyl-CoA synthetase (FATP/Acsvl) family are
emerging as key players in the trafficking of exogenous fatty
acids into the cell and in intracellular fatty acid homeostasis.We
have expressed twonaturally occurring splice variants of human
FATP2 (Acsvl1) in yeast and 293T-REx cells and addressed their
roles in fatty acid transport, activation, and intracellular traf-
ficking.Althoughboth forms (FATP2a (Mr 70,000) andFATP2b
(Mr 65,000 and lacking exon3, which encodes part of the ATP
binding site)) were functional in fatty acid import, only FATP2a
had acyl-CoA synthetase activity, with an apparent preference
toward very long chain fatty acids. To further address the roles
of FATP2a or FATP2b in fatty acid uptake and activation, LC-
MS/MS was used to separate and quantify different acyl-CoA
species (C14–C24) and to monitor the trafficking of different
classes of exogenous fatty acids into intracellular acyl-CoA
pools in 293T-REx cells expressing either isoform. The use of
stable isotopically labeled fatty acids demonstrated FATP2a is
involved in the uptake and activation of exogenous fatty acids,
with a preference toward n-3 fatty acids (C18:3 and C22:6).
Using the same cells expressing FATP2a or FATP2b, electro-
spray ionization/MS was used to follow the trafficking of stable
isotopically labeled n-3 fatty acids into phosphatidylcholine and
phosphatidylinositol. The expression of FATP2a resulted in the
trafficking of C18:3-CoA and C22:6-CoA into both phosphati-
dylcholine and phosphatidylinositol but with a distinct prefer-
ence for phosphatidylinositol. Collectively these data demonstrate
FATP2a functions in fatty acid transport and activation and pro-
vides specificity toward n-3 fatty acids in which the corresponding
n-3 acyl-CoAs are preferentially trafficked into acyl-CoA pools
destined for phosphatidylinositol incorporation.
Most evidence to date supports the notion that the distribu-
tion and trafficking of fatty acids into complex lipids of cells and
tissues is non-random and is distinct and characteristic of a
specific cell type or an intracellular compartment. How these
distinct patterns are generated andmaintained is poorly under-
stood, but it is reasonable to expect that the source of the fatty
acid, either from endogenous or exogenous sources, will lead to
different metabolic fates. These processes are likely governed
by proteins and enzymes, which function in fatty acid uptake
andmetabolic trafficking. Previously it has been very difficult to
distinguish these fatty acid trafficking events, but advances in
mass spectrometry has provided the requisite tools to resolve
these outstanding questions and to define the role(s) of specific
proteins involved in metabolic trafficking. In this work we have
employed stable isotopically labeled fatty acids to address the
roles of the human fatty acid transport proteins in fatty acid
uptake, activation, and trafficking into complex lipids.
Different members of the fatty acid transport protein/very
long chain acyl-CoA synthetase (FATP/Acsvl)2 and long chain
acyl-CoA synthetase (Acsl) families of proteins are emerging as
likely players in both fatty acid transport and intracellular traf-
ficking (1–4). All Acsl isoforms and many FATP isoforms acti-
vate fatty acid to yield acyl-CoA; in the context of fatty acid
transport, one mechanism that is operational is vectorial acyla-
tion, which results in the formation of acyl-CoA concomitant
with transport (1). In Escherichia coli, a single Acsl functions in
this process by activating in excess of 98% of exogenous fatty
acid to acyl-CoA, thereby linking transport with downstream
metabolism. This enzyme also functions in intracellular fatty
acid trafficking and phospholipid turnover as part of normal
fatty acid homeostasis (5–7). Evidence for vectorial acylation as
a mechanism driving fatty acid import in eukaryotic cells is less
well defined. In the context of fatty acid activation, the Acsls
have highest activity toward C16-C20 fatty acids and display
some discrimination with regard to saturation (2, 4, 8). The
FATPs, by comparison, activate very long and branched chain
fatty acids, and several also function in the transport of long
chain fatty acids and thus have distinguishing transport and
activation substrate preferences for each process (1, 4, 9–25). In
both yeast and adipocytes, there is evidence that specific FATP
and Acsl isoforms form a complex that functions in vectorial* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
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acylation to allow long chain fatty acid uptake and activation to
occur coordinately (19, 25).
Recent studies in mammalian systems suggest the FATP and
Acsl isoforms provide central roles in metabolic movement of
fatty acids into complex lipid pools (26). Overexpression stud-
ies examining the function of Acsl1, for example, demonstrated
that this enzyme provides an important role in triglyceride syn-
thesis in cardiacmyocytes, hepatocytes, andNIH3T3 cells (27–
29). TriacsinC (anAcsl inhibitor) treatment results in amarked
decrease in long acyl-CoA synthetase activity in fibroblasts that
parallels with a decrease in fatty acid incorporation into triglyc-
eride (30). Knockdown studies ofAcsl5 in hepatocytes results in
reduced exogenous fatty acid incorporation into triglycerides,
phospholipids, and cholesterol esters (31). Members of the
FATP family have significant homologies to the Acsls and
indeed function in the activation of very long chain fatty acids
(10). The overexpression of FATP1 in 293 cells channels exog-
enous fatty acids into triglyceride synthesis (32). Taken
together, it is clear the different FATP and Acsl isoforms have
unique functions in fatty acid partitioning and downstream
metabolism and thus provide different roles in maintaining
fatty acid homeostasis (33).
To investigate the roles of human FATP2 and a unique splice
variant, FATP2b, in fatty acid uptake and downstream metab-
olism, we have employed fatty acids labeledwith stable isotopes
and traced their metabolic fates using high resolution mass
spectrometry. Previous studies on the FATPs and Acsls have
been hampered by the inability to monitor and distinguish
unique metabolic pools of endogenous versus exogenous fatty
acids. However, the development of highly sensitive mass spec-
trometry techniques to monitor the metabolism of substrates
labeled with stable isotopes affords the opportunity to investi-
gate the dynamic nature of themetabolome (34–36). For exam-
ple these approaches have been used to identify and quantify
specific biomarkers for various disease states (35, 37–39). In
this work, different classes of fatty acids labeled with C13 or
deuterium have been used to monitor the formation of acyl-
CoA and downstream metabolic trafficking in cells expressing
FATP2a or FATP2b. These studies revealed novel insights into
the roles provided by these members of the FATP family of
proteins in determining the selectivity and specificity of acyl-
CoA formation from exogenous fatty acids and their subse-
quent trafficking into complex lipids.Of particular notewas the
finding that FATP2a has a unique metabolic phenotype with a
preference for generating CoA derivatives of n-3 fatty acids,
which are preferentially trafficked into phosphatidylinositol.
EXPERIMENTAL PROCEDURES
Generation of Yeast Cells Expressing FATP2a and FATP2b—
Watkins et al. (40) first described FATP2a as very long chain
acyl-CoA synthetase Acsvl1 (FATP2 variant 1, NCBI reference
sequence NM_003645.3). FATP2b, obtained from the Image
Consortium library (clone 30348317; FATP2 variant 2, NCBI
reference sequence NM_001159629.1) lacks exon 3, which
encodes a region of the protein that contains part of the ATP
binding domain and is required for adenylate formation (ATP/
AMP motif). Saccharomyces cerevisiae strain LS2086 contain-
ing deletions within the FAT1 and FAA1 genes (fat1faa1;
MATa ura3 52 his3200 ade2-101 lys2-801 leu2-3,112
faa1::HIS3 fat1::G418) were transformed with pDB121-de-
rived plasmids expressing FATP2a (pDB128) or FATP2b
(pDB126) along with the GAL4 transcription factor fusion vec-
tor, pRS416Gal4-ER-VP16. Transformation of yeast used
standard lithium acetate procedures (41). The details of
pDB126 have been previously described (24). pDB128 was gen-
erated by PCR amplification of the cDNA containing human
Acsvl1 (40) using primers 5-GC ATA GCC CTC GAG ATG
CTT TCC GCC ATC TAC ACA-3 and 5-CGC AGA CCA
AGC TTT CAG AGT TTC AGG GTT TTA GC-3, which
resulted in XhoI and HinDIII restriction sites, respectively.
Cloning FATP2a and FATP2b into pDB121 facilitated expres-
sion from the galactosidase promoter of a T7-tagged fusion
protein, which allows detection. Plasmids were propagated in
E. coli strain DH5 and the sequences of both clones were ver-
ified. Yeast cells were grown in yeast minimal medium with
dextrose containing 0.67% yeast nitrogen base, 2% dextrose,
adenine (20 mg/liter), and uracil (20 mg/liter), and the follow-
ing amino acids were added as required: 20 mg/liter arginine,
tryptophan, methionine, histidine, and tyrosine, 30 mg/liter
lysine, and 100mg/liter leucine). For expression of FATP2a and
FATP2b, the cells were subcultured to aA600 of 0.02 in the same
medium containing 10 nM -estradiol, grown tomid-log-phase
(0.8–1.2 A600), harvested, and then resuspended in PBS to a
final density of 6  107 cells/ml before dispensing into a
96-well assay plate for transport measurements or collected
by centrifugation for Western blots or acyl-CoA synthetase
measurements.
Generation of 293T-REx Stable Cell Lines Allowing the Con-
trolled Expression of FATP2a and FATP2b—The coding
sequences for FATP2a and FATP2b were amplified by PCR
using the primers 5-GCA TAG CCA AGC TTG ATG CTT
TCCGCCATCTACAC-3 and 5-CGCAGACCCTCGAGG
AGT TTC AGG GTT TTA GCA CT-3 generating HinDIII
and XhoI restriction sites, respectively, from the yeast expres-
sion clones (detailed above), cloned into pcDNA4/TO/myc-His
(Invitrogen), and propagated in E. coli strain JM109; the
sequences of both expression cloneswere verified. Stable 293T-
REx cell lines (Invitrogen; stably expressing the tetracycline
repressor protein) expressing FATP2a and FATP2b were gen-
erated as follows. Cells were seeded at 1  106 cells in 60-mm
dishes in DMEM medium containing 10% FBS and 5 g/ml
blasticidin; 24 h after seeding cells were transfected with 30 g
of pcDNA4 FATP2a (pDB312), pcDNA4 FATP2b (pDB311),
LacZ (control), or empty vector (control) using 293 Fectin
(Invitrogen). 24 h post-transfection 125 g/ml zeocin was
added to the media. 48 h after transfection the cells were
reseeded at 5.0 103 cells/cm2 in 6-well plates containing fresh
medium supplemented with 5g/ml blasticidin and 125g/ml
zeocin. The selectivemediumwas replaced every 3–4days until
foci were visible. Several clones of each were isolated using
cloning rings and expanded into 96-well plates. When cells
were more than 90% confluent they were split 1:3 in the same
surface area; the cells were subsequently expanded into a larger
surface area using a 12-well plate.
Induction of expression of FATP2a or FATP2b was accom-
plished by the addition of tetracycline to a final concentration
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of 2g/ml for 48 h; the cells were harvested and then subjected
to analytical studies as detailed below. Proteins expressed from
the pcDNA4 vector contain a c-myc epitope tag, which facili-
tated expression monitoring using Western blots, and a c-myc
antibody.
Fatty Acid Transport—The patterns of fatty acid transport
were monitored using the live cell, real-time method by meas-
uring the accumulation of the fluorescently labeled long chain
fatty acid, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-in-
dacene-3-dodecanoic acid, C1-BODIPY-C12, employing trypan
blue as the extracellular quenching agent (42).
To monitor fatty acid transport in yeast, strain LS2086 was
co-transformed with the pDB121-derived constructs express-
ing FATP2a or FATP2b and pRS416Gal4-ER-VP16. Cells were
grown as detailed above and resuspended in PBS to a final den-
sity of 6  107 cells/ml before dispensing into a 96-well assay
plate (75 l/well). 75 l of the C1-BODIPY-C12 transport mix-
ture (2.5MC1-BODIPY-C12, 1.5M fatty acid-free BSA, 4mM
Trypan blue) were added to each well. The cell-associated fluo-
rescence, reflective of fatty acid transport, was measured using
a Bio-Tek Synergy HT multidetection microplate reader (Bio-
Tek Instruments, Inc. Winooski, VT) using filter sets of 485
20 nmexcitation and 528 20 nmemission.Data are expressed
as arbitrary fluorescence units/3 106 cells/30 min.
The roles of FATP2a and FATP2b in fatty acid transport
were defined using the stable 293T-REx cell lines grown under
standard conditions in the presence of tetracycline (2 g/ml)
(see above) in optically transparent 96-well plates. Cells were
seeded at 50,000 cells per 96-well in standardmedia containing
5 g/ml blasticidin and 125 g/ml zeocin. 24 h after plating 2
g/ml tetracycline was added to the cells for induction. 48 h
post-induction cells were serum-starved for 1 h in minimum
Eagle’s medium without phenol red (50 l) before performing
the C1-BODIPY-C12 transport assay (42). Subsequently, 50 l
of the C1-BODIPY-C12 mixture (varying concentrations of
C1-BODIPY-C12 (0.5–32M as detailed in Fig. 3A), 10M fatty
acid-free BSA, 4 mM trypan blue) was added to each well, and
transportwasdeterminedbymeasuring thecell-associated fluo-
rescence as detailed above. Data were expressed as arbitrary
fluorescence units/min/106 cells. The cell number in each well
was determined using a standard Hoechst assay used to quan-
tify DNA. The fluorescence was read at 350/450 nm (excita-
tion/emission). The cell numberwas calculated froma standard
curve generated for cell number versus fluorescence units.
Acyl-CoA Synthetase Activity Determinations—Yeast cells
and 293T-REx cells expressing FATP2a or FATP2bwere grown
under inducing conditions as detailed above. For acyl-CoA syn-
thetase determination, yeast cells were collected by centrifuga-
tion (5000  g, 15 min); the media in the 293T-REx cells was
aspirated off, and cells washed once with 5 ml of PBS,
trypsinized using standard procedures, and collected by centri-
fugation. The cell pellets (yeast or 293T-REx cells) were resus-
pended in 1ml of STE lysis buffer (10mMTris-HCl, pH 8.0, 100
mM NaCl, 1 mM EDTA) and sonicated to lyse the cells on ice.
Samples were clarified by centrifugation (5000  g, 15 min);
supernatants were transferred to new tubes and assayed for
acyl-CoA synthetase activities as detailed below; protein con-
centrations were determined using the Bradford assay using
bovine serum albumin as a standard.
Acyl-CoA synthetase activities were determined using a
reaction mixture containing 50 mM Tris-HCl, pH 8.0, 10 mM
ATP, 10 mM MgCl2, 0.01% Triton X-100, 0.3 mM DTT, 50 M
[3H]oleic acid (C18:1) or [3H]lignoceric acid (C24:0) (dissolved in
10 mg/ml -cyclodextrin). The addition of coenzyme A (to a
final concentration of 0.2 mM) initiated the reaction. Samples
were incubated at 30 °C for 20min, and the reaction was termi-
nated by the addition of 2.5 ml of Dole’s reagent (isopropyl
alcohol, n-heptane, 1 M H2SO4 (40:10:1)) (43). The unesterified
fatty acidwas removed throughorganic extraction usingn-hep-
tane. Acyl-CoA formed during the reaction remained in the
aqueous fraction and was quantified by scintillation counting.
Data were expressed as nmol or pmol of acyl-CoA formed/
min/mg of protein.
Western Blotting to Monitor Protein Expression—The ex-
pression of FATP2a and FATP2b was monitored using
Western blot analysis using c-myc (Invitrogen) or T7
(Invitrogen) coupled with the appropriate secondary anti-
bodies. The concentrations of the primary and secondary
antibodies were used as recommended by the manufacturer
or experimentally determined. Detection was accomplished
using enhanced chemiluminescence.
Expression Patterns of FATP2a and FATP2b Assessed Using
RT-PCR—RT-PCR was used to detect the expression of
FATP2a and FATP2b in eight different human tissues. cDNAs
used in the PCR reactions were prepared from total RNA from
brain, liver, placenta, and heart (obtained from BioChain, Hay-
ward, CA). Total RNA (1 g) was used to synthesize cDNA
using the Bio-Rad I-script cDNA synthesis kit according to
manufacturer’s conditions. The parameters for cDNA synthe-
sis were 25 °C (5 min), 42 °C (30 min), and 85 °C (5 min). Fully
synthesized cDNAs were from colon, white adipose tissue,
small intestine, and kidney were also obtained from BioChain.
PCR was performed using the oligonucleotide pairs 5-CAA
CTG AAC CTA TCC CAG AG-3 (forward primer) and
5-CTG AAT GAC AGT GAC GTT G-3 (reverse primer).
These primers were designed to amplify regions upstream and
downstream of exon 3, which provided a distinction between
the FATP2a and FATP2b PCR products. PCR products were
expected to be 326 bp (FATP2a, exon 3 present) and 167 bp
(FATP2b, exon 3 is missing). PCR was performed using 1 l of
the cDNA mixture (prepared as detailed above or obtained
commercially), 0.5 M concentrations of each oligonucleotide
primer, 0.2 mM dNTPs, and 1 unit of Taq polymerase (Roche
Applied Science) in a final volume of 50 l. PCR parameters
included: 95 °C (5min) followed by 35 cycles of 30 s (95 °C), 30 s
(46 °C), and 45 s (72 °C); the final extension step was held at
72 °C for 10 min. The PCR products were resolved using non-
denaturing polyacrylamide gel electrophoresis and visualized
using ethidium bromide.
Stable Isotope Labeling and Fatty Acyl-CoA Extraction—For
stable isotope labeling experiments, 293T-REx cells were cul-
tured and induced as described above. 48 h after induction with
tetracycline, the cells were starved for 1 h in serum-depleted
minimum Eagle’s medium. The cells were then treated with 50
M U-13C- or 2H-labeled fatty acids for 4 h ([U-13C]C16:0
FATP2 Trafficking of n-3 Fatty Acids
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(Cambridge Isotope Laboratories, Inc.), [U-13C]C18:0 (Isotec/
Sigma), [U-13C]C18:1 (Medical Isotope, Inc.), [U-13C]C18:2
(n-6) (Cambridge Isotope Laboratories, Inc.), [U-13C]C18:3
(n-3) (Medical Isotope, Inc.), [2H8]C20:4 (n-6) (Isotec/Sigma),
[2H5]C22:6 (n-3) (Isotec/Sigma), and [2H47]C24:0) (C/D/N iso-
topes, Inc.). After treatment with stable isotopically labeled
fatty acids, the cells were then washed with 100 M BSA in
Hanks’ buffer. To collect the sample for fatty acyl-CoA analysis,
cells were scraped off the culture dish, resuspended in 5 ml of
PBS, and then harvested by centrifugation. The cell pellets were
resuspended in 0.5ml of water, and 0.2ml of the cell suspension
was immediately put on ice for fatty acyl-CoA extraction. Fatty
acyl-CoA extraction methods were adopted from Haynes et al.
(36). In brief, the cells were sonicated for 30 s after the addition
of 0.5ml of 1mMEDTA inmethanol. Chloroform (0.25ml) and
100 pmol of each internal standard (C17:0 CoA, C19:0 CoA,
and C23:0 CoA) were added to each sample. The cells were
sonicated again for 30 s and then incubated in a 50 °C water
bath for 30 min. After the addition of chloroform (0.25 ml) and
water (0.25 ml), the mixture was vortexed and centrifuged at
3000 rpm for 5 min. The upper phase was collected, and 0.5 ml
of water/methanol/chloroform (45:50:5 (v/v)) was added to the
bottom phase followed by centrifugation for phase separation.
This step was repeated one additional time to extract addi-
tional acyl-CoAs from the samples. Finally, 0.18 ml metha-
nol/butanol/chloroform (50:25:25) mixture was added, and
the fatty acyl-CoA extracts were stored at 80 °C until ana-
lyzed by LC-electrospray ionization tandem mass spectrom-
etry (LC-ESI/MS/MS).
LC-ESI/MS/MS Analysis of Fatty Acyl-CoA—Fatty acyl-
CoAs were separated by reverse phase HPLC using a C18
reverse phase column (Phenomenex Gemini; 2  150 mm,
5-m particle size) applying a binary flow of 0.25 ml/min at
40 °C. Elution gradient steps were as follows: 100% A, 5 min;
gradient to 60% B, 5 min; gradient to 100% B, 1 min; 100% B, 5
min on a Shimadzu system as previously detailed (36). Buffer A
(water/acetonitrile (85:15) 0.05% triethylamine (TEA)) and
Buffer B (water/acetonitrile (10:90), 0.05% TEA) were used as
the mobile phases. A Phenomenex Gemini guard column (2
4 mm) was routinely used to prefilter the acyl-CoA extracts.
The injection volume for LC-ESI/MS/MS analysis was 30 l.
The C18 column was re-equilibrated with 100% A for 5 min
between runs.
Fatty acyl-CoAs were detected and quantified using (ESI/
MS/MS) in the positive ion mode using a linear ion trap qua-
drupole mass spectrometer (4000 QTrap; AB Sciex Instru-
ments) that was operated using the methods previously
described (36, 44) with some modifications. Under these con-
ditions, the fatty acyl-CoAs fragments into fatty acylpantethine
and phosphoadenosine diphosphate. To monitor the different
acyl-CoA species, theMS scans for ions that have a neutral loss
of 507Da,which corresponds to the loss of the phosphoadenos-
ine diphosphate group. Multiple reaction monitoring scans
were set up to detect the precursor ion (MH) and the prod-
uct ion that results after fragmentation of each particular acyl-
CoA. The ion pairsmonitored for fatty acyl-CoA standards and
stable isotopically labeledCoAs are detailed inTable 1. For total
acyl-CoA profile analysis, each CoA species was quantified
using standard curvemeasurements produced for each individ-
ual acyl-CoA. To quantify labeled CoAs enrichments, peak
areas for these unique analytes were compared with peak areas
of the internal standard CoAs (C17:0-CoA, C19:0-CoA, and
C23:0-CoA). Analyte monitoring and quantification were con-
ducted with Analyst 1.5 Software from AB Sciex.
ESI/MS Analysis of Stable Isotopically Labeled Phospholipids—
Total lipids were extracted from cells labeled with stable isoto-
pically labeled fatty acids using methods established by Bligh
and Dyer (45). A mixture of phospholipid Internal standards
(PC 13/13 and PI 16/16) was added to each sample during the
first lipid extraction step for subsequent analyte quantification.
Total lipid extractions were diluted in solvent A (methanol/
isopropyl alcohol/water (70:5:25), 10 mM ammonium formate)
to a final dilution of 1:50. Phospholipids were analyzed with a
linear ion trap quadrupole mass spectrometer (4000 QTrap)
manufactured by AB Sciex Instruments. This system is also
equipped with two Shimadzu LC20ADXR LC pumps, a Shi-
madzu CBM20A LC controller, and a Shimadzu SIL20AC
autosampler, which allowed samples to be automatically
infused into the ESI source using flow injection ESI/MS meth-
ods (46–48). Infusion conditions included directly infusing
samples into the source using a 50 l injection loop at a flow
rate of 0.05 ml/min with Solvent A and Solvent B (methanol/
isopropyl alcohol/water (94:5:1), 10 mM ammonium formate)
as the mobile phases. To monitor PC species, precursor scans
were conducted in the positive ion mode to detect precursor
ions ofm/z 184. The 184 ion corresponds to the head group of
PC, which results after fragmentation. PI molecular species
were analyzed by neutral loss scanning for ions that result from
the neutral loss of 277m/z, which corresponds to the loss of the
PI head group. Fatty acid composition was determined for PC
and PI molecular species that exhibited a mass that corre-
sponded to a species that was labeled with a stable isotope
labeled fatty acid. PC and PI species labeled with [2H5]C22:6
had a mass of M5, whereas those labeled with [U-13C]C18:3
had a mass of M18. Fatty acid fragments from these unique
peaks were analyzed by MS/MS scans to confirm fatty acid
incorporation into PC and PI species. Analyte monitoring and
quantification are conductedwithAnalyst Version 1.5 Software
TABLE 1
Multiple reaction monitoring pairs and ESI/MS conditions for fatty
acyl-CoA species monitored by ESI/MS/MS
Multiple reaction monitoring scans were in the positive ion mode; dwell time for
each analyte was 80 ms. DP, declustering potential; CE, collision energy; CXP, col-
lision cell exit potential; RT, retention time (min); n 3.
Fatty acyl-CoA Q1 mass Q3 mass DP, CE, CXP LC RT (S.E.)
Da Da eV min
Internal standards
C17:0-CoA 1020.4 513.4 200, 54, 14 13.08 (0.27)
C19:0-CoA 1048.4 541.4 200, 54, 14 13.71 (0.20)
C23:0-CoA 1104.5 597.5 200, 54, 15 14.84 (0.27)
Stable isotopically labeled fatty acyl-CoA
U-13C	C16:0-CoA 1022.4 515.4 200, 54, 11 12.84 (0.27)
U-13C	C18:0-CoA 1052.4 545.4 200, 53, 14 13.21 (0.12)
U-13C	C18:1-CoA 1050.4 543.3 200, 54, 14 13.29 (0.10)
U-13C	C18:2-CoA 1048.4 541.4 200, 54, 14 12.52 (0.09)
U-13C	C18:3-CoA 1046.4 539.4 200, 54, 11 13.13 (0.21)
2H8	C20:4-CoA 1062.4 555.4 210, 55, 15 13.01 (0.16)
2H5	C22:6-CoA 1083.4 576.4 200, 54, 14 12.25 (0.15)
2H47	C24:0-CoA 1165.4 658.5 210, 54, 14 15.07 (0.26)
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from AB Sciex and the Online LipidomeDB Data Calculation
Environment, developed andmanaged by the Kansas Lipidom-
ics Research Center and K-INBRE Bioinformatics Core Facility
to quantify phospholipid molecular species (49).
RESULTS
Features of FATP2a and FATP2b—Fig. 1 illustrates the
genome organization of the human FATP2 (Acsvl1) locus
(15q21.2). The gene is 54,158 nucleotides in length and is pre-
dicted to contain 10 exons. In comparing the sequences from
FATP2a (obtained from liver) and FATP2b (obtained from pla-
centa), we found that the latter lacked exon 3, which encodes
part of the coreATP/AMPmotif (I) and the gate region (IV).On
the basis of directed mutagenesis in a number of different acyl-
CoA synthetases and FATPs and the crystal structure of the
Thermus thermophilus acyl-CoA synthetase, the ATP/AMP
motif contributes to ATP binding, whereas the gate provides
fatty acid access after nucleotide binding (50–53). The core
FATP/Acsvl motif (II), shown to be involved in fatty acid trans-
port in the yeast orthologue, remained intact (51). These data
predicted that FATP2b would be unable to activate fatty acids
to CoA thioesters.
Functional Studies of FATP2a and FATP2b When Expressed
in the fat1 faa1 Strain of Yeast—To address the roles of
FATP2a and FATP2b in both fatty acid transport and fatty acid
activation, we generated clones that allowed expression in
yeast. As a host, we employed the fat1 faa1 yeast strain 1) as
it is unable to transport long chain fatty acids, 2) has 
10%
wild-type long chain acyl-CoA synthetase activity (contributed
by Faa4p)(13), and 3) is unable to activate very long chain fatty
acids (11). This provided a well defined heterologous system to
distinguish transport and activation functions. Both FATP2a
and FATP2b were expressed from the galactosidase promoter
as detailed under “Experimental Procedures” as protein fusions
with a T7 epitope (Fig. 1, inset). As expected, FATP2b was
slightly smaller than FATP2a, giving aMr on SDS gels of 65,000
compared with 70,000 for FATP2a. This was consistent with
FATP2b lacking the 53-amino acid segment encoded within
exon3. Long chain fatty acid transport was assessed using
C1-BODIPY-C12 as a surrogate fatty acid under conditions well
established in our laboratory (42). Both FATP2a and FATP2b
were proficient in long chain fatty acid transport (Table 2).
These data indicated that although FATP2b lacked part of the
ATP/AMP motif and the gate region, it could still function in
fatty acid transport.
We next addressed the contributions of FATP2a and
FATP2b to long and very long acyl-CoA synthetase activities.
Expression of FATP2a and FATP2b did not increase oleoyl-
CoA synthetase activities above the vector control consistent
with the conclusion that neither provided long chain acyl-CoA
synthetase activity (Table 3). In contrast, only FATP2a was able
to activate very long chain fatty acids. These data collectively
indicated that FATP2bwas catalytically inactive as an acyl-CoA
FIGURE 1.Organization of FATP2a and FATP2b. Shown is an overview of FATP2a and FATP2b in relationship to the FATP2 gene. I represents the ATP/AMP
motif; IV is the gate region; II is the FATP/VLACS motif (upper); shown is alignment of amino acid sequences of human FATPs in regions (I (ATP/AMP motif), II
(FATP/VLACS motif), and IV (gate)). The numbers refer to the first amino acid residue in the selected regions. Inset, expression of FATP2a and FATP2b in yeast
using Western blots of the fat1 faa1 strain of yeast expressing FATP2a and FATP2b probed with anti-T7 in relationship to the vector control.
TABLE 2
C1-BODIPY-C12 transport in the yeast fat1 faa1 strain expressing
human FATP2a or FATP2b
Vector controls are the same cells transformed with pDB121. AFU, arbitrary fluo-





ap 0.05 using a paired t test relative to vector control.
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synthetase, but when expressed in yeast and like FATP2a
enhanced the transport of exogenous long chain fatty acids. On
the basis of our previous work showing that the yeast FATP
(Fat1p) and a long chain acyl-CoA synthetase (Acsl; Faa1p or
Faa4p) form a functional complex at themembrane, we suspect
that both FATP2a and FATP2b were able to partner with the
yeast Acsl Faa4p to promote the transport of long chain fatty
acids via vectorial acylation (25). This work verified predictions
made using alanine-scanning mutagenesis of yeast Fat1p,
which identified specific amino acid residues that distinguished
fatty acid transport from very long chain fatty acid activation
(51). In the present case we have demonstrated the naturally
occurring isoforms FATP2a and FATP2b both function in fatty
acid uptake but differ in their ability to activate very long chain
fatty acids.
Tissue Expression Patterns of FATP2a and FATP2b—The
original clones for FATP2a and FATP2b were obtained from
human liver and placenta, respectively. Using primers flanking
exon 3, we used RT-PCR to address whether both splice vari-
ants were expressed in eight different tissues, including liver
and placenta (Fig. 2). Both forms of FATP2 were expressed in
placenta, liver, and intestine; however, the expression of
FATP2b was always much lower relative to FATP2a. Although
there was expression of FATP2a in brain, heart, colon, and kid-
ney, we were unable to detect reproducible expression of
FATP2b. Interestingly there was no expression of either
FATP2a or FATP2b in white adipose tissue.
Functional Studies of FATP2a and FATP2b in 293T-REx
Cells—To further address the differential activities of FATP2a
and FATP2b, we expressed these proteins in 293T-REx cell
lines as detailed under “Experimental Procedures.” The target
gene was cloned into pcDNA4/TO/myc-His, which allowed
regulated expression from the Tet promoter. On the basis of
array data for the 293T-REx parent line, HEK 293, the expres-
sion of FATP2 is very low (54), and thus this cell linewas ideal to
address the function of these FATP2 variants in a mammalian
host. We first assessed the patterns of long chain fatty acid
transport using a live cell assay employing the fluorescent long
chain fatty acid C1-BODIPY-C12 (Fig. 3A). Expression of both
FATP2a and FATP2b increased the levels of fatty acid trans-
port, although FATP2a was more proficient (
30% higher
when comparedwith cells expressing FATP2b). The expression
of both FATP2a and FATP2b using tetracycline were compara-
ble and were routinely monitored using Western blots (inset,
Fig. 3A).
We next assessed long chain and very long chain acyl-CoA
synthetase activities in cells expressing FATP2a or FATP2b
(Fig. 3, B and C). Neither FATP2a nor FATP2b increased long
chain acyl-CoA synthetase activity using oleate as a substrate,
FIGURE 2. Tissue-specific expression of the FATP2 variants. RT-PCR using
primers illustrated as arrows in Fig. 1 of cDNA were prepared from total RNA
obtained from placenta (P), liver (L), brain (B), and heart (H) and cDNA from
colon (C), small intestine (I), white adipose tissue (A), and kidney (K); lanes
FATP2b and FATP2a are the controls respectively;MW represents the molec-
ular weight markers. The large arrow indicates the RT-PCR products corre-
sponding to FATP2a; the small arrows highlight the RT-PCR products corre-
sponding to FATP2b.
FIGURE 3. A, fatty acid transport in 293T-REx cells expressing FATP2a, FATP2b, or LacZ using varying C1-BODIPY-C12 concentrations. The inset is a Western blot
illustrating expression of FATP2a and FATP2b in 293T-REx cells (using c-myc antibody). The error bars represent the S.E. (n 3 or 4). AFU, arbitrary fluorescence
units. Long chain (oleoyl-) (B) and very long chain (lignoceryl-) (C) CoA synthetase activities in 293T-REx cells expressing FATP2a or FATP2b are shown; the
vector and LacZ controls are shown for reference to define background levels. The error bars represent the S.E. (n 4). *, p 0.05 relative to vector control
(paired t test).
TABLE 3
Acyl-CoA synthetase activities using long chain and very long chain
substrates in the yeast fat1 faa1 strain expressing human FATP2a
or FATP2b
Vector controls are the same cells transformed with pDB121. Data are S.E.; n 3.
Acyl-CoA synthetase activity (S.E.)
C18:1 C24:0
nmol/min/mg protein pmol/min/mg protein
Vector 3.4 (0.3) 1.6 (0.3)
FATP2a 4.4 (0.9) 22.9 (3.2)a
FATP2b 4.7 (0.7) 1.2 (0.2)
a p 0.001 using a paired t test relative to vector control.
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indicating both lacked this activity. On the other hand, only
FATP2a was able to activate very long chain fatty acids, which
necessarily requires the ATP binding region of the protein con-
tributed by exon 3 verifying data obtained using the yeast
model. Importantly, the finding that FATP2b was catalytically
inactive toward very long chain fatty acids but still functioned in
the transport of long chain fatty acids is consistent with a prob-
able interaction with a specific Acsl. The yeast FATP mutant
S258A-Fat1p lacks very long chain acyl-CoA synthetase activity
yet retains the ability to transport the long chain fatty acid
oleate (51). In essence, our previous work identified a point
mutant in the ATP/AMP motif in the yeast FATP that retains
transport activity but is essentially devoid of acyl-CoA synthe-
tase activity; as a naturally occurring variant, FATP2b hasmany
similar characteristics.
Steady State acyl-CoA Levels in 293T-REx Cells Expressing
FATP2a or FATP2b—Apart from uptake of exogenous fatty
acids, we chose to further assess the roles of FATP2a and
FATP2b in endogenous fatty acidmetabolismbymeasuring the
steady state levels of the different acyl-CoA species in 293T-
REx cells expressing these isoforms using LC-ESI/MS/MS
(Table 4; Fig. 4). Considering that the specificity of acyl-CoA
synthetase activity attributed to FATP2 is for very long chain
fatty acids, we expected the corresponding acyl-CoA species to
be increased by overexpression of FATP2a alone. Although the
total acyl-CoA levels were increased by
20% in cells express-
ing FATP2a when compared with those defined for cells
expressing FATP2b or transformed with the vector (Table 4),
we could not detect a significantly different amount of any indi-
vidual species (Fig. 4). This may be because the activated fatty
acids are metabolized quickly into more complex lipid species
and do not accumulate.
Trafficking of Exogenous Stable Isotopically Labeled Fatty
Acids into Acyl-CoA Pools in 293T-REx Cells Expressing
FATP2a or FATP2b—We next assessed the trafficking of exog-
enous fatty acids into acyl-CoA pools using stable isotopically
labeled fatty acids ([U-13C]C16:0, [U-13C]C18:0, [U-13C]C18:1,
[U-13C]C18:2 (n-6), [U-13C]C18:3 (n-3), [2H8]C20:4 (n-6),
[2H5]C22:6 (n-3), [2H47]C24:0) in 293T-REx cells expressing
FATP2a or FATP2b. These experiments were designed to
address whether FATP2a, in particular, had an impact on the
uptake and activation of different species of fatty acids com-
pared with FATP2b, which is catalytically inactive. Using this
approach acyl-CoAs synthesized from exogenous stable isoto-
pically labeled fatty acids could be identified and distinguished
from those generated from internal pools. We first examined
the formation of acyl-CoA using 50 M [U-13C]C16:0,
[U-13C]C18:0, [U-13C]C18:1, or [2H47]C24:0 as exogenous fatty
acids. For these fatty acids, the levels of the resulting acyl-CoA
were comparable between cells expressing FATP2a and
FATP2b (Fig. 5, A–C) with the exception of the very long chain
fatty acid, lignocerate, where the corresponding acyl CoA
increased just over 2-fold in cells expressing FATP2a. Unique
and interesting patterns started to emerge when the n-6 fatty
acids [U-13C]C18:2 and [2H8]C20:4 were supplied exogenously
to cells expressing FATP2a or FATP2b. Arachidonyl-CoA for-
mation in particular was increased 
30% in cells expressing
FATP2a when compared with those expressing FATP2b (Fig.
6). Of significance was the finding that cells expressing FATP2a
were able to form acyl-CoA derivatives from exogenous n-3
fatty acids, [U-13C]C18:3 and [2H5]C22:6, to levels that were
3–5-fold higher than cells expressing FATP2b or harboring the
vector alone (Fig. 7). Collectively, these data support the con-
clusion that FATP2a had a preference in the generation of
intracellular acyl-CoAs derived from C18:3 and C22:6. More
FIGURE 4. Acyl-CoA profiles of 293T-REx cells expressing FATP2a or
FATP2b.After inductionof expressionof FATP2a (gray bars) or FATP2b (white
bars), cells were harvested, and acyl-CoAs were extracted as described under
“Experimental Procedures.” Acyl-CoA extractions were separated and ana-
lyzed using LC-ESI/MS/MS (the black bars represent cells transformed with
vector and also subjected to the same inducing conditions). Individual acyl-
CoA levels were calculated from standard curves using AB Sciex Analyst soft-
ware Version 1.5. The error bars represent the S.E. (n 5).
TABLE 4
Acyl-CoA levels in 293T-REx cells expressing FATP2a or FATP2b
Total acyl-CoA levels were defined for each cell type by summing the levels defined







FIGURE5. Isotopically labeledacyl-CoAprofiles in293T-RExcellsexpress-
ing FATP2a or FATP2b. 293T-REx cells expressing FATP2a or FATP2b were
labeled with 50 M [U-13C]C16:0 (A), [U-13C]C18:0 (B), [U-13C]C18:1 (C), or
[2H47]C24:0 (D) for 4 h, and isotopically labeled acyl-CoAs were determined
using LC-ESI/MS/MS as detailed under “Experimental Procedures.” The error
bars represent the S.E. (n 3or 4). *,p 0.05 relative to vector control (paired
t test).
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broadly, these findings clearly advance our understanding of
members of the FATP family in general by showing particular
isoforms (in this case FATP2a) provided a role in the formation
of specific acyl-CoAs derived from exogenous fatty acids.
Trafficking of n-3 Acyl-CoAs into Phosphatidylcholine and
Phosphatidylinositol—The finding that the expression of
FATP2a increased n-3 acyl-CoAs from exogenous n-3 fatty
acids provided for the first time novel insights into the specific-
ity of an individual FATP isoform. Of interest was whether
these acyl-CoAswere selectively trafficked into different classes
of phospholipids. To this end, we interrogated the phosphati-
dylcholine and phosphatidylinositol pools after incubation of
cells expressing FATP2a or FATP2b with [U-13C]C18:3 or
[2H5]C22:6 using ESI/MS (Figs. 8 and 9). These phospholipid
classes were chosen because PC is themost abundant phospho-
lipid in the cell and PI is known to be enriched in n-3 and n-6
fatty acids. There was no difference in [U-13C]C18:3 in PC
detected between cells expressing empty vector, FATP2a, or
FATP2b. There was a trend for elevated [2H5]C22:6 in PC for
cells expressing FATP2a but not FATP2b. In contrast, PI pools
were more heavily labeled than PC pools when cells were chal-
lenged with either fatty acid species, and cells expressing
FATP2a in particular caused an enrichment of both labels in PI
(Fig. 9). We noted that the amount of PI labeled with
[2H5]C22:6 significantly exceeded that of labeled PC by 8-fold
(Table 5).
DISCUSSION
In the present studywe report for the first time the functional
characterization of two variants of human FATP2, one of which
lacks 53 amino acids from exon 3 that encodes a portion of the
ATP/AMP motif required for adenylate formation. We
employed two different heterologous expression systems to
address the roles of these proteins in fatty acid transport and
activation. Both FATP2a and FATP2b were functional in the
long chain fatty acid transport pathway; FATP2a had very long
chain acyl-CoA synthetase activity, whereas FATP2b was cata-
FIGURE8.AnalysisofFATP2a(graybars)-andFATP2b(whitebars)-mediated
fattyacid incorporation intophosphatidylcholinemolecularspeciesbyESI/
MS. 293T-REx cells expressing FATP2a or FATP2b were labeled with 50 M
[U-13C]C18:3 (A) or [2H5]C22:6 (B) for 4h, and isotopically labeledPC specieswere
analyzed using ESI/MS as detailed under “Experimental Procedures.” The black




MS. 293T-REx cells expressing FATP2a or FATP2b were labeled with 50 M
[U-13C]C18:3 (A) or [2H5]C22:6 (B) for 4 h, and isotopically labeled PI species were
analyzed using ESI/MS as detailed under “Experimental Procedures.” The black
bars are control cells transformed with the vector; error bars represent the S.E.
(n 3).
FIGURE 6. Isotopically labeled n-6 acyl-CoA profiles in 293T-REx cells
expressingFATP2aorFATP2b.293T-RExcells expressingFATP2aor FATP2b
were labeled with 50 M [U-13C]C18:2 (A) or [2H8]C20:4 (B) for 4 h, and isoto-
pically labeled acyl-CoAs were determined using LC-ESI/MS/MS as detailed
under “Experimental Procedures.” The error bars represent theS.E. (n3or 4).
FIGURE 7. Isotopically labeled n-3 acyl-CoA profiles in 293T-REx cells
expressingFATP2aorFATP2b.293T-RExcells expressingFATP2aor FATP2b
were labeled with 50 M [U-13C]C18:3 (A) or [2H5]C22:6 (B) for 4 h, and isoto-
pically labeled acyl-CoAs were determined using LC-ESI/MS/MS as detailed
under “Experimental Procedures.” The error bars represent theS.E. (n3or 4).
*, p 0.05; **, p 0.01 relative to vector control (paired t test).
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lytically inactive. Although these results were expected based
on our previous work using alanine-scanning mutagenesis of
the yeast FATP (51), the data acquired using fatty acids labeled
with stable isotopes, indicating a preference for long chain poly-
unsaturated substrates, were not anticipated and provided
novel insights into the role the fatty acid transport proteins
provide in fatty acid homeostasis.
Of particular importance was the finding that FATP2a
expression resulted in increased acyl-CoA formation from
exogenous n-3 fatty acids and to a lesser extent the n-6 fatty
acid, arachidonate. Previous work characterizing FATP2 as
Acsvl1 demonstrated this enzyme had specificity for very long
chain saturated fatty acids (55). This work verified these studies
by showing FATP2a significantly increased intracellular ligno-
ceryl CoA pools in response to exogenous lignocerate as a pro-
totypical very long chain saturated fatty acid. There was no
evidence fromour labeling studies that FATP2a or FATP2bhad
a significant impact on the activation of long chain fatty acids
(C16:0, C18:0, andC18:1). Thus, we propose that FATP2a func-
tions in the fatty acid transport and activation pathways, with a
preference toward the n-3 fatty acids.
The in vivo role of FATP2b is less clear, but the evidence
provided here strongly supports a role for this protein in fatty
acid uptake apart from activation as evidenced by measuring
transport in both yeast and 293T-REx cells expressing FATP2b.
The identification of a naturally occurring variant of FATP2,
which functions in the transport of exogenous fatty acids but
lacks activation activity, confirms our earlier work using ala-
nine-scanning mutagenesis of the yeast FATP (Fat1p). Of note
was the identification and characterization of the mutant form
S258A-Fat1p in the ATP/AMP motif, which functioned in the
transport pathway but lacked very long chain acyl-CoA synthe-
tase activity (51). Pointmutants have also been generated in the
ATP/AMP motif in FATP1 and FATP4 that reduced or elimi-
nated, respectively, fatty acid transport as measured using flow
cytometry of paraformaldehyde-fixed cells after incubation
withC1-BODIPY-C12 (53, 57). The apparent difference in some
of the results reported here and these previous publications
may stem from the specific fatty acid transport assays used; in
the present study we have employed a live cell real time assay to
monitor the transport of the fluorescent fatty acidC1-BODIPY-
C12 as opposed to paraformaldehyde fixed cells and flow cytom-
etry. Alternatively, these data may reflect specific functional
differences in the different FATP isoforms.
ESI/MS analyses of stable isotopically labeled phospholipids
provided novel evidence that FATP2a has a preference for acti-
vating n-3 essential fatty acids from an exogenous source,
which are then trafficked preferentially into phosphatidylinosi-
tol. Interestingly, our data indicate the n-3 acyl-CoAs generated
fromFATP2awere channeled into non-oxidative pathways and
more specifically into PI. These findings represent a significant
advance in our understanding of themechanisms that promote
the selective import and trafficking of different classes of fatty
acids. This work also validates the use of exogenous isotopically
labeled fatty acids, which after activation are channeled into
downstream metabolic pools, including complex lipids. The
use of mass spectrometry to trace the formation of acyl-CoA
provided important insights into the roles provided by the
FATP isoforms. More specifically our finding that FATP2a
preferentially promoted the formation of n-3 acyl-CoAs from
exogenous fatty acids argues these proteins may function as
molecular determinates in providing specificity; the resulting
acyl-CoAs arising from different fatty acid species are likely to
have distinct metabolic fates. Using the tools developed in the
study, we are in a position to more fully address the roles pro-
vided by othermembers of the FATP family in fatty acid uptake,
activation and trafficking, focusing on specificity in the forma-
tion of acyl-CoA and in the selective trafficking into down-
stream metabolic pools.
We have used RT-PCR to semiquantitatively assess the
expression of both FATP2a and FATP2b in various tissues and
consistently found both were expressed in placenta, liver, and
intestine; we could only detect FATP2a expression in brain kid-
ney, colon, and heart. In the tissue types where we could meas-
ure FATP2b expression, those levels were consistently low and
well below the expression levelsmeasured for FATP2a.Adipose
tissue did not express either form of FATP2. Steinberg et al.
(40), in their work describing FATP2a as Acsvl1, found that
expression was most prominent in liver and kidney. Although
the physiological role of FATP2 in fatty acid utilizing tissues is
not well defined, there are some interesting studies that indi-
cate this protein may function in very specialized roles in fatty
acid transport and trafficking. Treatment of pregnant mice
with rosiglitazone increases the expression of FATP1 and
FATP4 in the placenta, which is coupled with a commensurate
increase in long chain fatty acid transport (58). This treatment,
however, results in marked changes in placental morphology
and lowers both placenta and embryo weights when compared
with mice treated with vehicle only. The most notable finding
and one thatwas not discussed in any detail was that the expres-
sion of FATP2 was significantly reduced. When these studies
are evaluated in the framework of the current study, it is worth
speculating that reducing the expression of FATP2 with a per-
oxisome proliferator-activated receptor  agonist results in the
placental abnormalities and lowered embryo weights noted
above. Perhaps in the context of placental function, the expres-
sion of FATP2 provides amechanism for selective uptake of n-3
fatty acids that are required for fetal growth and development.
In conclusion, the current studies demonstrate for the first time
that FATP2 is expressed as two alternative isoforms.Our data fur-
TABLE 5
Incorporation of 2H5	C22:6 and U]
13C	C18:3 into phosphatidylcholine and phosphatidylinositol in 293T-REx cells expressing FATP2a
Label PC (S.E.)a PI (S.E.)a -Fold difference (PI/PC) (S.E.)
% %
2H5	C22:6 0.25 (0.08) 1.48 (0.40)b 8.19 (3.37)
U-13C	C18:3 1.02 (0.35) 1.52 (0.55) 2.21 (1.32)
aNumbers represent the percent of total labeled 2H5	C22:6 or U13C	C18:3 incorporated into PC and PI; n 3 or 4.
bp 0.05 using a paired t test relative to PC.
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ther clarify the dual and distinct functions of FATP2 in long chain
fatty acid uptake and very long chain fatty acid activation. The
information gleaned using stable isotopically labeled fatty acids
indicate a previously undisclosed role for FATP2 in the metabo-
lism of polyunsaturated fatty acids. The approaches we have used
to assess FATP2 functions may now be adapted to evaluate addi-
tional FATP isoforms to uncover unique or overlapping functions
in metabolic processing of fatty acids.
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